Research in castrationresistant prostate cancer: What does the future hold?

Current Oncology

Volumn 17, Issue SUPPL. 2, 2010, Pages

  MacFarlane, Robyn J ^a   Chi, K N ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Castration resistant prostate cancer; Novel therapy; Targeted therapy

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; AD 4054; AFLIBERCEPT; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; BICALUTAMIDE; CHAPERONE; CLUSTERIN; DOCETAXEL; ENDOTHELIN 1; KETOCONAZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MDV 3100; MITOXANTRONE; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; OGX 011; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; PROVENGE; SUNITINIB; TENSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY CANCER; LUNG CANCER; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SEIZURE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 78149489985     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i0.702     Document Type: Article

References (58)

1. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64.
2. Oosterhof GO, Roberts JT, de Reijke TM, et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase iii study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003;44:519-26.
3. Saad F, Gleason DM, Murray R, et al. A randomized, placebocontrolled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68.
4. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
5. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
6. De Bono JS, Oudard S, Ozguroglu M, et al. for the tropic Investigators. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mcrpc) previously treated with docetaxel: final results of a multinational phase iii trial (tropic) [abstract 4508]. Proc Am Soc Clin Oncol 2010;28:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=74&abstractID=44106; cited June 14, 2010]
7. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
8. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 2008;26:1148-59.
9. Heidenreich A, Aus G, Bolla M, et al. eau guidelines on prostate cancer. Eur Urol 2008;53:68-80.
10. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550-5.
11. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
12. Mohler JL, Gregory CW, Ford OH 3rd, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-8.
13. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653-7.
14. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.
15. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27.
16. Locke JA, Guns ES, Lubik aa, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68:6407-15.
17. Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69:16-22.
18. Attar RM, Jeur-Kunkel M, Balog A, et al. Discovery of BMS- 641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer. Cancer Res 2009; 69:6522-30.
19. Attard G, Reid AH, Yap TA, et al. Phase i clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563-71.
20. Ryan C, Efstathios E, Smith M, et al. Phase ii multicenter study of chemotherapy (chemo)-naïve castration-resistant prostate cancer (crpc) not exposed to ketoconazole (keto), treated with abiraterone acetate (aa) plus prednisone [abstract 5046]. Proc Am Soc Clin Oncol 2009;27:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=65&abstractID=34693; cited June 8, 2010]
21. Reid AH, Attard G, Danila D, et al. A multicenter phase ii study of abiraterone acetate (aa) in docetaxel pretreated castration-resistant prostate cancer (crpc) patients (pts) [abstract 5047]. Proc Am Soc Clin Oncol 2009;27:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=65&abstractID=34016; cited June 8, 2010]
22. Danila DC, de Bono J, Ryan CJ, et al. Phase ii multicenter study of abiraterone acetate (aa) plus prednisone therapy in docetaxeltreated castration-resistant prostate cancer (crpc) patients (pts): impact of prior ketoconazole (keto) [abstract 5048]. Proc Am Soc Clin Oncol 2009;27:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=65&abstractID=31591; cited June 8, 2010]
23. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in a phase i/ii study of castration-resistant prostate cancer (crpc) [abstract 5011]. Proc Am Soc Clin Oncol 2009;27:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=65 &abstractID=34746; cited June 8, 2010]
24. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 2001;61:2736-43.
25. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on cancer and leukemia group B 9480. Clin Cancer Res 2001;7:1932-6.
26. Picus J, Halabi S, Rini B, et al. The use of bevacizumab (b) with docetaxel (d) and estramustine (e) in hormone refractory prostate cancer (hrpc): initial results of calgb 90006 [abstract 1578]. Proc Am Soc Clin Oncol 2003;22:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=23&abstractID=101428; cited June 8, 2010]
27. Verheul HM, Hammers H, van Erp K, et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 2007;13:4201-8.
28. Isambert N, Freyer G, Zanetta S, Falandry C, Soussan Lazard K, Fumoleau P. A phase i dose escalation and pharmacokinetic (pk) study of intravenous aflibercept (vegf trap) plus docetaxel (d) in patients (pts) with advanced solid tumors: preliminary results [abstract 3599]. Proc Am Soc Clin Oncol 2008;26:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=55&abstractID=30715; cited June 8, 2010]
29. Sonpavde G, Periman PO, Bernold D, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010;21:319-24.
30. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 2003;278:11590-600.
31. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 2005;7:909-15.
32. Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 1999;274:6875-81.
33. Ammar H, Closset JL. Clusterin activates survival through the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2008;283:12851-61.
34. Gleave M, Chi KN. Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers. Ann N Y Acad Sci 2005;1058:1-15.
35. Miyake H, Nelson C, Rennie PS, Gleave ME. Testosteronerepressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2006;60:170-6.
36. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002;50:179-88.
37. Chi KN, Eisenhauer E, Fazli L, et al. A phase i pharmacokinetic and pharmacodynamic study of OGX-011, a 2 ́-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005;97:1287-96.
38. Chi KN, Siu LL, Hirte H, et al. A phase i study of OGX-011, a 2 ́-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008;14:833-9.
39. Saad F, Hotte SJ, North SA, et al. A phase ii randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (hrpc) who relapsed on or within six months of 1st-line docetaxel therapy [abstract 5002]. Proc Am Soc Clin Oncol 2008;26:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=55&abstractID=32032; cited June 8, 2010]
40. Chi KN, Hotte SJ, Yu E, et al. A randomized phase ii study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (hrpc) [abstract 5069]. Proc Am Soc Clin Oncol 2007;25:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=47&abstractID=30401; cited June 8, 2010.
41. Chi KN, Hotte SJ, Yu E, et al. Mature results of a randomized phase ii study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer [abstract 5012]. Proc Am Soc Clin Oncol 2009;27:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=65&abstractID=30398; cited June 8, 2010.
42. Mousses S, Wagner U, Chen Y, et al. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 2001;20:6718-23.
43. Gera JF, Mellinghoff IK, Shi Y, et al. Akt activity determines sensitivity to mammalian target of rapamycin (mtor) inhibitors by regulating cyclin D1 and C-myc expression. J Biol 2004;279:2737-46.
44. Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, Ghosh PM. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 2008;27:7106-17.
45. Yoshimoto M, Cunha IW, Coudry RA, et al. fish analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007;97:678-85.
46. Higano CS, Alumkal JJ, Ryan CJ, et al. A phase ii study of cixutumumab (IMC-A12), a monoclonal antibody (mab) against the insulin-like growth factor i receptor (igf-ir), monotherapy in metastatic castration resistant prostate cancer (mcrpc): feasibility of every 3-week dosing and updated results [abstract 189]. Proc Am Soc Clin Oncol Genitourin Cancer Symp 2010;:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=73&abstract ID=30567; cited June 8, 2010]
47. Amato RJ, Jac J, Mohammad T, Saxena S. Pilot study of rapamycin in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer 2008;6:97-102.
48. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944-9.
49. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase ii, placebo-controlled trial. J Clin Oncol 2003;21:679-89.
50. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110:1959-66.
51. Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008;113:2478-87.
52. Armstrong AJ, Creel P, Turnbull J, et al. A phase i-ii study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2008;14:6270-6.
53. James ND, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2008:55:1112-23.
54. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone- refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894-903.
55. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase iii trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:30-94.
56. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115:3670-9.
57. Kantoff P, Higano CS, Berger ER, et al. Updated survival results of the impact trial of sipuleucel-T for metastatic castration-resistant prostate cancer (crpc) [abstract 8]. Proc Am Soc Clin Oncol Genitourin Cancer Symp 2010;:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=73&abstractID=30778; cited June 8, 2010]
58. Higano CS, Corman JM, Smith DC, et al. Phase 1/2 doseescalation study of a gm-csf-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008;113:975-84.